Boston Scientific Corporation
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Boston Scientific Corporation sits in the top decile of US sponsors by registered trial count (#122 of 15,742 sponsors by registered trial count).
Boston Scientific Corporation: 280 sponsored US clinical trials, 22 recruiting.
Boston Scientific Corporation sponsors 280 registered US clinical trials on ClinicalTrials.gov, 22 of them currently recruiting, and 207 completed. 59 of these trials are in Phase 3-4 (later-stage) and 23 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Coronary Artery Disease, with 8 trials.
Top-decile sponsor footprint
Boston Scientific Corporation ranks in the top decile of sponsors by registered trial count (#122 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
207 of 239 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
280 total, page 3 of 6
NAVITAS and ENVISION - Study to Characterize Select Objective Metrics & Clinical Outcomes in Chronic Pain Patients With Boston Scientific Neurostimulation Systems
NCT03240588
Multicenter Automatic Defibrillator Implantation Trial With Subcutaneous Implantable Cardioverter Defibrillator
NCT02787785
Strategic MAnagement to Optimize Response To Cardiac Resynchronization Therapy Registry
NCT03075215
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
NCT03064126
Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation
NCT02928497
WallFlex Pancreatic Metal Stent for Pancreatic Duct Strictures
NCT02802020
iNod System Human Feasibility Assessment
NCT02832284
Study to Characterize Effects of Programming in SCS Patients Undergoing a Temporary Trial
NCT02988713
Postmarket Registry for Evaluation of the Superion® Spacer
NCT04087811
A TheraSphere® Advanced Dosimetry Retrospective Global Study in HCC
NCT03295006
Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP
NCT02923726
Prospective Registry on User Experience With The Mapping System For Ablation Procedures
NCT02698670
Self-Centering Guide Catheter Feasibility Study
NCT02639494
EVOLVE Short DAPT Study
NCT02605447
Multicenter Study of Cryoablation for Palliation of Painful Bone Metastases
NCT02511678
Ablation Efficacy of Contact Side Firing Fiber in Predefined Settings for Treating BPH
NCT02683980
Utilizing Holmium Laser for FURS Renal Stone Lithotripsy Comparing Stone Breaking vs. Stone Dusting Settings
NCT02683993
ENABLE MRI (Magnetic Resonance Imaging)
NCT02652481
ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent
NCT02574481
A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma
NCT02460991
The Captivator EMR Registry
NCT02482701
CoverEdge Algorithm Programming Study
NCT02492880
Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism
NCT02396758
Understanding Outcomes With the EMBLEM™ S-ICD in Primary Prevention Patients With Low Ejection Fraction
NCT02433379
COMFORT: A Multicenter, Open-label, Randomized, Crossover Study
NCT02462720
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
NCT02392351
Pre-operative Biliary SEMS RCT During Neoadjuvant Therapy
NCT02238847
Short Term Pancreatic Stenting Registry
NCT02262845
A Study to Evaluate the Effect of Precision Spectra™ Programming Features and Lead Options on Patient Outcomes
NCT02384096
Effectiveness of the Precision Spinal Cord Stimulator System at Sub-Perception Amplitude
NCT02314000
PLATINUM Diversity
NCT02240810
Quadripolar CRT-D On Currently Approved Lead SystemS
NCT02232984
Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement
NCT02202434
The SENTRY Clinical Study
NCT01975090
Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System
NCT02159521
VIRTUS: An Evaluation of the Vici™ Venous Stent System in Patients With Chronic Iliofemoral Venous Outflow Obstruction
NCT02112877
GreenLight XPS Laser System Retrospective Chart Review
NCT02139969
Evaluation of ACUITY™ X4 Quadripolar Coronary Venous Leads and RELIANCE™ 4-FRONT Defibrillation Leads
NCT02071173
Study of Cryoablation for Metastatic Lung Tumors
NCT01957787
Evaluation of Automatic Threshold Algorithms
NCT02097290
Safety and Effectiveness Study of the Precision SCS Systems Adapted for High-Rate Spinal Cord Stimulation
NCT02093793
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
NCT01887717
Xenform Postmarket Surveillance Study
NCT01945580
LONGEVITY Study. Evaluation of the Device and Battery Longevity of Boston Scientific Market-released ICD and CRT-D Devices
NCT02091011
LVRC IDE Crossover Study (Crossover From IDE Trial CLN0009)
NCT02059057
Uphold LITE Post-Market Surveillance Study
NCT01917968
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
NCT01912339
CUSTOM-DBS: Current Steering to Optimize Deep Brain Stimulation
NCT01896115
Post Market Study Of Single Incision Sling Versus Transobturator Sling for Stress Urinary Incontinence
NCT01784588
Deep Brain Stimulation (DBS) for the Treatment of Parkinson's Disease
NCT01839396
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 16 |
| Phase 3 | 33 |
| Phase 4 | 26 |
Therapeutic Areas
Where Boston Scientific Corporation enrollment is open (later-stage tilt)
22 recruiting of 280 indexed (8% open); 207 completed (74%).
Phase mix: 59 late (III/IV) vs 23 early (I/II) (later-stage heavy).
Top condition: Coronary Artery Disease (8 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Boston Scientific Corporation: open-pipeline peers nationwide
Peers matched on 280 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Boston Scientific Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 280 trials (± recruiting share)
- Regeneron Pharmaceuticals · 280 trials · 22% recruiting
- Alcon Research · 275 trials · 2% recruiting
- Eisai · 287 trials · 2% recruiting
- SWOG Cancer Research Network · 270 trials · 10% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 8% recruiting · 305 trials
- Novo Nordisk A/S · 8% recruiting · 431 trials
- Hoffmann-La Roche · 8% recruiting · 909 trials
- United Therapeutics · 8% recruiting · 63 trials
Related
What to do with this Boston Scientific Corporation page
280 registered trials is a research-attention snapshot, not an endorsement of Boston Scientific Corporation or any single study.
- 22 of Boston Scientific Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Coronary Artery Disease is the condition Boston Scientific Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Coronary Artery Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Boston Scientific Corporation pipeline card: 280 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.